Spyre Therapeutics (SYRE) total liabilities
Spyre Therapeutics (SYRE) had total liabilities of $62.55M at the end of fiscal 2025 (December 31, 2025). That is 31.0% lower than the $90.68M of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total liabilities, fiscal 2025
- $62.55M
- Change on fiscal 2024
- −31.0%
- Growth, 5 years
- +23.5% a year
- Growth, 10 years
- +37.7% a year
- Highest on record
- $157.84Mfiscal 2023
- Lowest on record
- $2.55Mfiscal 2015
- Fiscal years on record
- 112015–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Spyre Therapeutics total liabilities, in more detail
Over the five fiscal years to 2025 total liabilities grew at a compound 23.5% a year; over ten years the rate was 37.7% a year. Across the 11 fiscal years on record (2015–2025), the highest was $157.84M in fiscal 2023 and the lowest $2.55M in fiscal 2015.
Total liabilities by fiscal year
Spyre Therapeutics total liabilities, year by year
| Fiscal year | Total liabilities | Change | Year ended |
|---|---|---|---|
| 2025 | $62.55M | 31.0% down | |
| 2024 | $90.68M | 42.6% down | |
| 2023 | $157.84M | 657.4% up | |
| 2022 | $20.84M | 19.8% down | |
| 2021 | $25.99M | 19.3% up | |
| 2020 | $21.79M | 5.7% down | |
| 2019 | $23.10M | 124.1% up | |
| 2018 | $10.31M | 79.6% up | |
| 2017 | $5.74M | 40.1% up | |
| 2016 | $4.10M | 60.7% up | |
| 2015 | $2.55M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.
How to read it
It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.
Total liabilities at health care companies of similar size
| Company | Total liabilities | Fiscal year |
|---|---|---|
| Vaxcyte PCVX | $317.21M | 2025 |
| Bio-Rad Laboratories BIO | $3.12B | 2025 |
| Molina Healthcare MOH | $11.50B | 2025 |
| Spyre Therapeutics SYRE | $62.55M | 2025 |
| Qiagen QGEN | $2.50B | 2025 |
| Insulet PODD | $1.68B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Spyre Therapeutics, figure by figure
- Spyre Therapeutics market cap
- Spyre Therapeutics revenue
- Spyre Therapeutics earnings
- Spyre Therapeutics earnings per share (EPS)
- Spyre Therapeutics P/E ratio
- Spyre Therapeutics P/S ratio
- Spyre Therapeutics P/B ratio
- Spyre Therapeutics free cash flow
- Spyre Therapeutics operating margin
- Spyre Therapeutics dividend
- Spyre Therapeutics shares outstanding
- Spyre Therapeutics total debt
- Spyre Therapeutics cash on hand
- Spyre Therapeutics total assets
- Spyre Therapeutics net assets (shareholders' equity)
- Spyre Therapeutics return on equity (ROE)
- Spyre Therapeutics return on invested capital (ROIC)
Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value
Spyre Therapeutics total liabilities: questions and answers
How large are Spyre Therapeutics's total liabilities?
Spyre Therapeutics (SYRE) had total liabilities of $62.55M at the end of fiscal 2025 (December 31, 2025). That is 31.0% lower than the $90.68M of fiscal 2024.
What is the growth rate of Spyre Therapeutics's total liabilities?
Over the five fiscal years to 2025 total liabilities grew at a compound 23.5% a year; over ten years the rate was 37.7% a year.
What are the highest and lowest total liabilities figures on record for Spyre Therapeutics?
Across the 11 fiscal years on record (2015–2025), the highest was $157.84M in fiscal 2023 and the lowest $2.55M in fiscal 2015.
How is Spyre Therapeutics's total liabilities calculated?
Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Spyre Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total liabilities
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Spyre Therapeutics (SYRE) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/total-liabilities
Underlying data: the company's filings with the SEC and Yahoo Finance.